Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Mochida Pharmaceutical Co., Ltd. ( (JP:4534) ).
Mochida Pharmaceutical Co., Ltd. has announced its decision to acquire 20% of And Pharma Co., Ltd., making it an equity-method affiliate, as part of its strategy to enhance its core pharmaceutical business. This acquisition aims to create synergies by combining Mochida’s expertise in biosimilar development with And Pharma’s manufacturing capabilities, while also collaborating with Itochu Corporation to strengthen the business foundation of And Pharma’s subsidiaries. The move is expected to contribute to a stable supply of pharmaceuticals and support Japan’s medical economy by providing high-quality generics and biosimilars.
The most recent analyst rating on (JP:4534) stock is a Hold with a Yen3460.00 price target. To see the full list of analyst forecasts on Mochida Pharmaceutical Co., Ltd. stock, see the JP:4534 Stock Forecast page.
More about Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. operates in the pharmaceutical industry with a focus on developing new drugs, generic drugs, including authorized generics and biosimilars, and has a strategic emphasis on global expansion. The company is structured around three business pillars: pharmaceutical, biomaterials, and healthcare, aiming to offer distinctive products that meet market needs.
YTD Price Performance: -6.43%
Average Trading Volume: 24,050
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen110.8B
Learn more about 4534 stock on TipRanks’ Stock Analysis page.